Phage Therapy for the Prevention and Treatment of Pressure Ulcers.

Pressure Ulcer Clinical Trial

Official title:

A Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Potential Efficacy of BACTELIDE vs. Placebo in Addition to Standard-of-care Therapy for S. Aureus, P. Aeruginosa, and K. Pneumoniae Colonized Pressure Injuries

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04815798
• Other study ID #: PGX-20001
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: January 2022
• Est. completion date: December 2023

Study information

• Verified date: December 2021
• Source: Phagelux Inc.
• Contact: Nancy Tawil, Ph.D.
• Phone: 1-800-243-0116
• Email: Nancy.tawil[@]phageluxcanada.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate a topical bacteriophage therapy product (BACTELIDE) as an adjunct to standard therapy for the prevention and treatment of pressure ulcers colonized with S. aureus, P. aeruginosa, or K. pneumoniae species.

This study will compare the safety and efficacy of BACTELIDE in conjunction with standard of care (SOC) versus a placebo in conjunction with standard of care.

Description:

The central aim of this study is to investigate the safety, tolerability, and indicative efficacy of a single dose of a phage therapy combination product, BACTELIDE, as an adjunct to standard therapy in participants presenting with a Stage II, III or IV pressure injuries with positive wound cultures for S. aureus, P. aeruginosa, or K. pneumoniae at screening.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 69
• Est. completion date: December 2023
• Est. primary completion date: August 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Provision of signed and dated informed consent form

2. Stated willingness to comply with all study procedures and availability for the duration of the study

3. Stated willingness to comply with lifestyle considerations

4. Male or female, 18 years or older presenting in long-term care facilities, out-patient department or in-hospital patients with a stage II, III or IV pressure injury with or without local signs of infection with a size not exceeding 28 cm2

5. Within 72 hours before randomization, pressure injury specimen positive for S. aureus, P. aeruginosa, or K. pneumoniae determined by qPCR or rapid diagnostic test or conventional method or positive growth on specific agar.

6. For females of reproductive potential: use of a highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of administration of the study intervention

7. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.

Exclusion Criteria:

1. Diagnosis of Kennedy terminal ulcer, Trombley-Brennan terminal tissue injuries or skin changes at life's end (SCALE).

2. Pregnancy or lactation.

3. Known allergic reactions to components of SilvaSorb hydrogel.

4. Known allergic reactions to components of the phage treatment; including known allergic reactions to bacteriophages, polyester amide urea polymers and/or TMN buffer.

5. Unstable coronary artery disease.

6. Patients diagnosed with Type I or Type II diabetes, uncontrolled (HgbA1c >8% or 2+ glycosuria).

7. Treatment with another investigational drug or other intervention within 30 days.

8. Intercurrent condition requiring a high dose of chronic corticosteroid therapy, immunosuppressive medication, oncologic chemotherapy.

9. Patients who have additional uncontrolled serious medical or psychiatric illness determined by the investigators where the patient is unfit to receive the product.

10. Chronic stool incontinence without a rectal tube if an individual has a sacral ulcer.

11. Placement of a wound vacuum.

12. Surgical wound closure planned within the study period.

13. Organ failure, acute respiratory failure and chronic renal failure.

14. Diagnosed osteomyelitis.

Related Conditions & MeSH terms

• Pressure Ulcer

Intervention

Combination Product:
• Bacteriophage-loaded Microcapsule Spray
Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages encapsulated in a biodegradable polymer. This bacteriophage product will be delivered topically every 3 days for 56 days or until wound has healed.
• Placebo
Placebo intervention consists of a dosage-metered airless spray containing a buffer solution analogous to the study intervention. This placebo will be delivered topically every 3 days for 56 days or until wound has healed.

Procedure:
• Standard of Care
Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Phagelux Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events coded by MedDra	Safety of BACTELIDE will be measured by the number and percent of treatment related adverse events.	At least 56 days
Primary	Incidence of treatment discontinuation due to adverse events	Tolerability of BACTELIDE will be measured by the percent premature discontinuation from the study intervention due to treatment emergent Adverse Events	56 days
Secondary	Assess if BACTELIDE can improve the clinical outcome by preventing or treating wound infection.	Response/improvement in treatment-specific clinical outcome based on change in PUSH tool scores.	28 days
Secondary	Assess the effect of BACTELIDE on the incidence of bacterial colonization by S. aureus, P. aeruginosa, or K. pneumoniae species in pressure injury wounds.	Change in the incidence of positive wound cultures for S. aureus, P. aeruginosa, K. pneumoniae collected from surface deep wound swabs and /or tissue specimens.	28 days
Secondary	Assess the effect of BACTELIDE on the rate of wound progression.	Rate of wound progression will be measured by change in viable tissue.	56 days